Spironolactone in chronic hemodialysis patients improves cardiac function
We performed this study to assess whether low dose spironolactone could be admi-nistered in hemodialysis (HD) patients with moderate to severe heart failure to improve cardio-vascular function and reduce hospitalization without inducing hyperkalemia. We enrolled 16 chro-nic HD patients with moderate...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2009-01-01
|
Series: | Saudi Journal of Kidney Diseases and Transplantation |
Subjects: | |
Online Access: | http://www.sjkdt.org/article.asp?issn=1319-2442;year=2009;volume=20;issue=3;spage=392;epage=397;aulast=Taheri |
id |
doaj-e2c8af0434f3415695a7eb65ff258537 |
---|---|
record_format |
Article |
spelling |
doaj-e2c8af0434f3415695a7eb65ff2585372020-11-24T22:09:09ZengWolters Kluwer Medknow PublicationsSaudi Journal of Kidney Diseases and Transplantation1319-24422009-01-01203392397Spironolactone in chronic hemodialysis patients improves cardiac functionTaheri ShahramMortazavi MojhganShahidi ShahrzadPourmoghadas AliGarakyaraghi MohammadSeirafian ShivaEshaghian AfroozGhassami MaryamWe performed this study to assess whether low dose spironolactone could be admi-nistered in hemodialysis (HD) patients with moderate to severe heart failure to improve cardio-vascular function and reduce hospitalization without inducing hyperkalemia. We enrolled 16 chro-nic HD patients with moderate to severe heart failure and left ventricle ejection fraction :5 45%. In a double blinded randomized placebo controlled study, one group of 8 patients received 25 mg of spi-ronolactone after each dialysis session within six months, and the rest received a placebo. Echo-cardiography was performed on all the patients to assess ejection fraction and left ventricular mass during 12 hours after completion of hemodialysis at the beginning and the end of study. Serum potassium was measured predialysis every 4 weeks. The mean ejection fraction increased signi-ficantly more in spironolactone group during the study period than in the placebo group (6.2 ± 1.64 vs. 0.83 ± 4.9, P= 0.046). The mean left ventricular mass decreased in the spironolactone group, but increased significantly in the placebo group during the period (-8.4 ± 4.72 vs. 3 ± 7.97. 95%, P= 0.021). The incidence of hyperkalemia was not significantly increased in the study or controlled groups. In conclusion, we found in this study that administration of spironolactone in chronic HD patients with moderate to severe heart failure substantially improved their cardiac function and decreases left ventricular mass without development of significant hyperkalemia.http://www.sjkdt.org/article.asp?issn=1319-2442;year=2009;volume=20;issue=3;spage=392;epage=397;aulast=TaheriEjection fraction (EF)HemodialysisHeart failureLeft ventricle (LV) massSpironolactone |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Taheri Shahram Mortazavi Mojhgan Shahidi Shahrzad Pourmoghadas Ali Garakyaraghi Mohammad Seirafian Shiva Eshaghian Afrooz Ghassami Maryam |
spellingShingle |
Taheri Shahram Mortazavi Mojhgan Shahidi Shahrzad Pourmoghadas Ali Garakyaraghi Mohammad Seirafian Shiva Eshaghian Afrooz Ghassami Maryam Spironolactone in chronic hemodialysis patients improves cardiac function Saudi Journal of Kidney Diseases and Transplantation Ejection fraction (EF) Hemodialysis Heart failure Left ventricle (LV) mass Spironolactone |
author_facet |
Taheri Shahram Mortazavi Mojhgan Shahidi Shahrzad Pourmoghadas Ali Garakyaraghi Mohammad Seirafian Shiva Eshaghian Afrooz Ghassami Maryam |
author_sort |
Taheri Shahram |
title |
Spironolactone in chronic hemodialysis patients improves cardiac function |
title_short |
Spironolactone in chronic hemodialysis patients improves cardiac function |
title_full |
Spironolactone in chronic hemodialysis patients improves cardiac function |
title_fullStr |
Spironolactone in chronic hemodialysis patients improves cardiac function |
title_full_unstemmed |
Spironolactone in chronic hemodialysis patients improves cardiac function |
title_sort |
spironolactone in chronic hemodialysis patients improves cardiac function |
publisher |
Wolters Kluwer Medknow Publications |
series |
Saudi Journal of Kidney Diseases and Transplantation |
issn |
1319-2442 |
publishDate |
2009-01-01 |
description |
We performed this study to assess whether low dose spironolactone could be admi-nistered in hemodialysis (HD) patients with moderate to severe heart failure to improve cardio-vascular function and reduce hospitalization without inducing hyperkalemia. We enrolled 16 chro-nic HD patients with moderate to severe heart failure and left ventricle ejection fraction :5 45%. In a double blinded randomized placebo controlled study, one group of 8 patients received 25 mg of spi-ronolactone after each dialysis session within six months, and the rest received a placebo. Echo-cardiography was performed on all the patients to assess ejection fraction and left ventricular mass during 12 hours after completion of hemodialysis at the beginning and the end of study. Serum potassium was measured predialysis every 4 weeks. The mean ejection fraction increased signi-ficantly more in spironolactone group during the study period than in the placebo group (6.2 ± 1.64 vs. 0.83 ± 4.9, P= 0.046). The mean left ventricular mass decreased in the spironolactone group, but increased significantly in the placebo group during the period (-8.4 ± 4.72 vs. 3 ± 7.97. 95%, P= 0.021). The incidence of hyperkalemia was not significantly increased in the study or controlled groups. In conclusion, we found in this study that administration of spironolactone in chronic HD patients with moderate to severe heart failure substantially improved their cardiac function and decreases left ventricular mass without development of significant hyperkalemia. |
topic |
Ejection fraction (EF) Hemodialysis Heart failure Left ventricle (LV) mass Spironolactone |
url |
http://www.sjkdt.org/article.asp?issn=1319-2442;year=2009;volume=20;issue=3;spage=392;epage=397;aulast=Taheri |
work_keys_str_mv |
AT taherishahram spironolactoneinchronichemodialysispatientsimprovescardiacfunction AT mortazavimojhgan spironolactoneinchronichemodialysispatientsimprovescardiacfunction AT shahidishahrzad spironolactoneinchronichemodialysispatientsimprovescardiacfunction AT pourmoghadasali spironolactoneinchronichemodialysispatientsimprovescardiacfunction AT garakyaraghimohammad spironolactoneinchronichemodialysispatientsimprovescardiacfunction AT seirafianshiva spironolactoneinchronichemodialysispatientsimprovescardiacfunction AT eshaghianafrooz spironolactoneinchronichemodialysispatientsimprovescardiacfunction AT ghassamimaryam spironolactoneinchronichemodialysispatientsimprovescardiacfunction |
_version_ |
1725813415188889600 |